PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-01-31

AUTHORS

V Serra, M Scaltriti, L Prudkin, P J A Eichhorn, Y H Ibrahim, S Chandarlapaty, B Markman, O Rodriguez, M Guzman, S Rodriguez, M Gili, M Russillo, J L Parra, S Singh, J Arribas, N Rosen, J Baselga

ABSTRACT

There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial studies with rapalogs, allosteric inhibitors of mTORC1, have resulted in limited clinical efficacy probably due to the release of a negative regulatory feedback loop that triggers AKT and ERK signaling. Since activation of AKT occurs via PI3K, we decided to explore whether PI3K inhibitors prevent the activation of these compensatory pathways. Using HER2-overexpressing breast cancer cells as a model, we observed that PI3K inhibitors abolished AKT activation. However, PI3K inhibition resulted in a compensatory activation of the ERK signaling pathway. This enhanced ERK signaling occurred as a result of activation of HER family receptors as evidenced by induction of HER receptors dimerization and phosphorylation, increased expression of HER3 and binding of adaptor molecules to HER2 and HER3. The activation of ERK was prevented with either MEK inhibitors or anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. Combined administration of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity compared with single agent PI3K inhibitors. Our findings indicate that PI3K inhibition in HER2-overexpressing breast cancer activates a new compensatory pathway that results in ERK dependency. Combined anti-MEK or anti-HER2 therapy with PI3K inhibitors may be required in order to achieve optimal efficacy in HER2-overexpressing breast cancer. This approach warrants clinical evaluation. More... »

PAGES

2547-2557

Journal

TITLE

Oncogene

ISSUE

22

VOLUME

30

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/onc.2010.626

DOI

http://dx.doi.org/10.1038/onc.2010.626

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006324258

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21278786


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Extracellular Signal-Regulated MAP Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphoinositide-3 Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-3", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Serra", 
        "givenName": "V", 
        "id": "sg:person.01124501356.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124501356.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
            "Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scaltriti", 
        "givenName": "M", 
        "id": "sg:person.0773414311.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773414311.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Pathology Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Molecular Pathology Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prudkin", 
        "givenName": "L", 
        "id": "sg:person.01272204511.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272204511.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eichhorn", 
        "givenName": "P J A", 
        "id": "sg:person.011163517524.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011163517524.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ibrahim", 
        "givenName": "Y H", 
        "id": "sg:person.01341267404.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341267404.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chandarlapaty", 
        "givenName": "S", 
        "id": "sg:person.0717331640.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717331640.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
            "Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Markman", 
        "givenName": "B", 
        "id": "sg:person.01056647353.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056647353.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodriguez", 
        "givenName": "O", 
        "id": "sg:person.0732111704.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732111704.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guzman", 
        "givenName": "M", 
        "id": "sg:person.0746262053.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746262053.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Molecular Pathology Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Molecular Pathology Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodriguez", 
        "givenName": "S", 
        "id": "sg:person.01163655237.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163655237.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gili", 
        "givenName": "M", 
        "id": "sg:person.01167560363.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167560363.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Russillo", 
        "givenName": "M", 
        "id": "sg:person.01052225453.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052225453.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parra", 
        "givenName": "J L", 
        "id": "sg:person.01344161011.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344161011.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Prometheus Therapeutics and Diagnostics, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Prometheus Therapeutics and Diagnostics, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singh", 
        "givenName": "S", 
        "id": "sg:person.012366035415.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012366035415.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituci\u00f3 Catalana de Recerca i Estudis Acan\u00e7ats, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain", 
            "Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain", 
            "Instituci\u00f3 Catalana de Recerca i Estudis Acan\u00e7ats, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arribas", 
        "givenName": "J", 
        "id": "sg:person.01231307272.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231307272.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosen", 
        "givenName": "N", 
        "id": "sg:person.01333626177.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333626177.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Experimental Therapeutics Program, Vall d\u2032Hebron Institute of Oncology, Barcelona, Spain", 
            "Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA", 
            "Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain", 
            "Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain", 
            "Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baselga", 
        "givenName": "J", 
        "id": "sg:person.01063677263.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063677263.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/onc.2008.432", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015615859", 
          "https://doi.org/10.1038/onc.2008.432"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012130507", 
          "https://doi.org/10.1038/nature04304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035598015", 
          "https://doi.org/10.1038/nrc2656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2008.490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044836961", 
          "https://doi.org/10.1038/onc.2008.490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.1890", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000532983", 
          "https://doi.org/10.1038/nm.1890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35052073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053565592", 
          "https://doi.org/10.1038/35052073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014023118", 
          "https://doi.org/10.1038/nrc839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm1962", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020910010", 
          "https://doi.org/10.1038/nrm1962"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature05933", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023428666", 
          "https://doi.org/10.1038/nature05933"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-01-31", 
    "datePublishedReg": "2011-01-31", 
    "description": "There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial studies with rapalogs, allosteric inhibitors of mTORC1, have resulted in limited clinical efficacy probably due to the release of a negative regulatory feedback loop that triggers AKT and ERK signaling. Since activation of AKT occurs via PI3K, we decided to explore whether PI3K inhibitors prevent the activation of these compensatory pathways. Using HER2-overexpressing breast cancer cells as a model, we observed that PI3K inhibitors abolished AKT activation. However, PI3K inhibition resulted in a compensatory activation of the ERK signaling pathway. This enhanced ERK signaling occurred as a result of activation of HER family receptors as evidenced by induction of HER receptors dimerization and phosphorylation, increased expression of HER3 and binding of adaptor molecules to HER2 and HER3. The activation of ERK was prevented with either MEK inhibitors or anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. Combined administration of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity compared with single agent PI3K inhibitors. Our findings indicate that PI3K inhibition in HER2-overexpressing breast cancer activates a new compensatory pathway that results in ERK dependency. Combined anti-MEK or anti-HER2 therapy with PI3K inhibitors may be required in order to achieve optimal efficacy in HER2-overexpressing breast cancer. This approach warrants clinical evaluation.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/onc.2010.626", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3788086", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2411202", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "22", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "keywords": [
      "PI3K inhibitors", 
      "anti-HER2 therapy", 
      "breast cancer", 
      "PI3K inhibition", 
      "ERK dependency", 
      "single-agent PI3K inhibitors", 
      "HER2-overexpressing breast cancer cells", 
      "HER2-overexpressing breast cancer", 
      "anti-HER2 monoclonal antibody", 
      "MEK inhibitors", 
      "superior anti-tumor activity", 
      "expression of HER3", 
      "compensatory pathways", 
      "limited clinical efficacy", 
      "ERK signaling", 
      "tyrosine kinase inhibitors", 
      "protein kinase B/mammalian target", 
      "kinase B/mammalian target", 
      "anti-tumor activity", 
      "breast cancer cells", 
      "clinical efficacy", 
      "result of activation", 
      "combined administration", 
      "activation of Akt", 
      "clinical evaluation", 
      "activation of ERK", 
      "optimal efficacy", 
      "strong rationale", 
      "HER2", 
      "compensatory activation", 
      "mammalian target", 
      "cancer", 
      "rapamycin (mTOR) pathway", 
      "monoclonal antibodies", 
      "family receptors", 
      "kinase inhibitors", 
      "cancer cells", 
      "PI3K", 
      "Akt activation", 
      "therapy", 
      "inhibitors", 
      "HER3", 
      "cell death", 
      "activation", 
      "adaptor molecule", 
      "efficacy", 
      "inhibition results", 
      "Akt", 
      "ERK", 
      "initial study", 
      "inhibition", 
      "pathway", 
      "negative regulatory feedback loop", 
      "regulatory feedback loop", 
      "signaling", 
      "receptor dimerization", 
      "allosteric inhibitors", 
      "disease", 
      "administration", 
      "receptors", 
      "antibodies", 
      "rapalogs", 
      "death", 
      "proliferation", 
      "induction", 
      "cells", 
      "expression", 
      "findings", 
      "release", 
      "phosphorylation", 
      "mTORC1", 
      "rationale", 
      "phosphatidylinositol", 
      "target", 
      "feedback loop", 
      "activity", 
      "evaluation", 
      "study", 
      "binding", 
      "resistance", 
      "results", 
      "molecules", 
      "model", 
      "dependency", 
      "approach", 
      "loop", 
      "dimerization", 
      "order", 
      "B/mammalian target", 
      "K inhibitors", 
      "K inhibition", 
      "agent PI3K inhibitors", 
      "new compensatory pathway", 
      "PI3K inhibition results", 
      "K inhibition results"
    ], 
    "name": "PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer", 
    "pagination": "2547-2557", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006324258"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/onc.2010.626"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21278786"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/onc.2010.626", 
      "https://app.dimensions.ai/details/publication/pub.1006324258"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_547.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/onc.2010.626"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.626'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.626'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.626'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.626'


 

This table displays all metadata directly associated to this object as RDF triples.

381 TRIPLES      22 PREDICATES      142 URIs      124 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/onc.2010.626 schema:about N1f0ab65e58f54ef282a6012f93bf54b5
2 N3159d3fa8df149d8857b05cb157adc18
3 N35e4beef2996442bad63a88ffa5eb0e3
4 N760c38fad12744dd911a1fad890e5981
5 N86303739686e41858008c5718553e4a2
6 N8675ddb7e85c48b2a61ca0b1fa7f02e6
7 Nae62979d43ae48efbad8c0642fe3777c
8 Nb64fc29b3fee4e94a5e6753ba8f221d0
9 Nc65fce65bae4456e827240d2620b8c4e
10 Ndd9bf0c2b60b4313842475acb25c95a6
11 Nf276d53305c0437fa5a671575d6a6c30
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author N52327333bb4f4b5fa6748fac50f34acf
15 schema:citation sg:pub.10.1038/35052073
16 sg:pub.10.1038/nature00766
17 sg:pub.10.1038/nature04304
18 sg:pub.10.1038/nature05933
19 sg:pub.10.1038/nm.1890
20 sg:pub.10.1038/nrc2656
21 sg:pub.10.1038/nrc839
22 sg:pub.10.1038/nrm1962
23 sg:pub.10.1038/onc.2008.432
24 sg:pub.10.1038/onc.2008.490
25 schema:datePublished 2011-01-31
26 schema:datePublishedReg 2011-01-31
27 schema:description There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial studies with rapalogs, allosteric inhibitors of mTORC1, have resulted in limited clinical efficacy probably due to the release of a negative regulatory feedback loop that triggers AKT and ERK signaling. Since activation of AKT occurs via PI3K, we decided to explore whether PI3K inhibitors prevent the activation of these compensatory pathways. Using HER2-overexpressing breast cancer cells as a model, we observed that PI3K inhibitors abolished AKT activation. However, PI3K inhibition resulted in a compensatory activation of the ERK signaling pathway. This enhanced ERK signaling occurred as a result of activation of HER family receptors as evidenced by induction of HER receptors dimerization and phosphorylation, increased expression of HER3 and binding of adaptor molecules to HER2 and HER3. The activation of ERK was prevented with either MEK inhibitors or anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. Combined administration of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity compared with single agent PI3K inhibitors. Our findings indicate that PI3K inhibition in HER2-overexpressing breast cancer activates a new compensatory pathway that results in ERK dependency. Combined anti-MEK or anti-HER2 therapy with PI3K inhibitors may be required in order to achieve optimal efficacy in HER2-overexpressing breast cancer. This approach warrants clinical evaluation.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N374871e8bb914ed2b7da1a4582036b66
32 N6c07b5e0a6814869b44805cdd0b344d0
33 sg:journal.1097543
34 schema:keywords Akt
35 Akt activation
36 B/mammalian target
37 ERK
38 ERK dependency
39 ERK signaling
40 HER2
41 HER2-overexpressing breast cancer
42 HER2-overexpressing breast cancer cells
43 HER3
44 K inhibition
45 K inhibition results
46 K inhibitors
47 MEK inhibitors
48 PI3K
49 PI3K inhibition
50 PI3K inhibition results
51 PI3K inhibitors
52 activation
53 activation of Akt
54 activation of ERK
55 activity
56 adaptor molecule
57 administration
58 agent PI3K inhibitors
59 allosteric inhibitors
60 anti-HER2 monoclonal antibody
61 anti-HER2 therapy
62 anti-tumor activity
63 antibodies
64 approach
65 binding
66 breast cancer
67 breast cancer cells
68 cancer
69 cancer cells
70 cell death
71 cells
72 clinical efficacy
73 clinical evaluation
74 combined administration
75 compensatory activation
76 compensatory pathways
77 death
78 dependency
79 dimerization
80 disease
81 efficacy
82 evaluation
83 expression
84 expression of HER3
85 family receptors
86 feedback loop
87 findings
88 induction
89 inhibition
90 inhibition results
91 inhibitors
92 initial study
93 kinase B/mammalian target
94 kinase inhibitors
95 limited clinical efficacy
96 loop
97 mTORC1
98 mammalian target
99 model
100 molecules
101 monoclonal antibodies
102 negative regulatory feedback loop
103 new compensatory pathway
104 optimal efficacy
105 order
106 pathway
107 phosphatidylinositol
108 phosphorylation
109 proliferation
110 protein kinase B/mammalian target
111 rapalogs
112 rapamycin (mTOR) pathway
113 rationale
114 receptor dimerization
115 receptors
116 regulatory feedback loop
117 release
118 resistance
119 result of activation
120 results
121 signaling
122 single-agent PI3K inhibitors
123 strong rationale
124 study
125 superior anti-tumor activity
126 target
127 therapy
128 tyrosine kinase inhibitors
129 schema:name PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
130 schema:pagination 2547-2557
131 schema:productId N1995fa9c986f43bf985207b396a64f2d
132 N7493768b471c4b5a9874fce7e560cc68
133 N9edea6f781fa49c9bfa2f2f8a438a8a3
134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006324258
135 https://doi.org/10.1038/onc.2010.626
136 schema:sdDatePublished 2022-01-01T18:25
137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
138 schema:sdPublisher Ne9b6107350a64849884355895599c8d4
139 schema:url https://doi.org/10.1038/onc.2010.626
140 sgo:license sg:explorer/license/
141 sgo:sdDataset articles
142 rdf:type schema:ScholarlyArticle
143 N1995fa9c986f43bf985207b396a64f2d schema:name doi
144 schema:value 10.1038/onc.2010.626
145 rdf:type schema:PropertyValue
146 N1a901348b922420c9f5dafe31e8ca58b rdf:first sg:person.0732111704.15
147 rdf:rest N9eff54118d5b44e6af24bb7c3f777521
148 N1f0ab65e58f54ef282a6012f93bf54b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Proto-Oncogene Proteins c-akt
150 rdf:type schema:DefinedTerm
151 N23cae45bf97d43369ff33adc7a9f4f0e rdf:first sg:person.01333626177.27
152 rdf:rest N7e018d7876664305947d1ed149925bff
153 N3159d3fa8df149d8857b05cb157adc18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Phosphoinositide-3 Kinase Inhibitors
155 rdf:type schema:DefinedTerm
156 N35e4beef2996442bad63a88ffa5eb0e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Cell Line, Tumor
158 rdf:type schema:DefinedTerm
159 N374871e8bb914ed2b7da1a4582036b66 schema:volumeNumber 30
160 rdf:type schema:PublicationVolume
161 N52327333bb4f4b5fa6748fac50f34acf rdf:first sg:person.01124501356.03
162 rdf:rest N9a77ce2d661e465ba7f7157857460c6b
163 N53f5fb29054e49e0a34af2265ef736fa rdf:first sg:person.0717331640.11
164 rdf:rest N8efc41234ca9445087c798f8c3c4e8f0
165 N5b20b007470a44c7bec7ea597b68506a rdf:first sg:person.01052225453.31
166 rdf:rest Nf08644a17383451fbf4edfa33affa0c2
167 N5dbd2f7732c346b3a8fefa1a25387559 rdf:first sg:person.01163655237.24
168 rdf:rest Nf056798079274712a03a2eed9eda875e
169 N6c07b5e0a6814869b44805cdd0b344d0 schema:issueNumber 22
170 rdf:type schema:PublicationIssue
171 N7493768b471c4b5a9874fce7e560cc68 schema:name dimensions_id
172 schema:value pub.1006324258
173 rdf:type schema:PropertyValue
174 N760c38fad12744dd911a1fad890e5981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 N7e018d7876664305947d1ed149925bff rdf:first sg:person.01063677263.55
178 rdf:rest rdf:nil
179 N86303739686e41858008c5718553e4a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name TOR Serine-Threonine Kinases
181 rdf:type schema:DefinedTerm
182 N8675ddb7e85c48b2a61ca0b1fa7f02e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Extracellular Signal-Regulated MAP Kinases
184 rdf:type schema:DefinedTerm
185 N8efc41234ca9445087c798f8c3c4e8f0 rdf:first sg:person.01056647353.90
186 rdf:rest N1a901348b922420c9f5dafe31e8ca58b
187 N96a350eea7bc407ea79c498e99559903 rdf:first sg:person.012366035415.05
188 rdf:rest Nd406f17eadec4e23a748402c6953b7c8
189 N9a77ce2d661e465ba7f7157857460c6b rdf:first sg:person.0773414311.69
190 rdf:rest Nba3926e56ef74c00bf7d64d2639a5b86
191 N9af0ca10e5eb42babd7249fab4d36b39 rdf:first sg:person.01341267404.42
192 rdf:rest N53f5fb29054e49e0a34af2265ef736fa
193 N9edea6f781fa49c9bfa2f2f8a438a8a3 schema:name pubmed_id
194 schema:value 21278786
195 rdf:type schema:PropertyValue
196 N9eff54118d5b44e6af24bb7c3f777521 rdf:first sg:person.0746262053.25
197 rdf:rest N5dbd2f7732c346b3a8fefa1a25387559
198 Nae62979d43ae48efbad8c0642fe3777c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Receptor, ErbB-3
200 rdf:type schema:DefinedTerm
201 Nafd6804f8de242c3bca4c06bda402d72 rdf:first sg:person.011163517524.50
202 rdf:rest N9af0ca10e5eb42babd7249fab4d36b39
203 Nb64fc29b3fee4e94a5e6753ba8f221d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Protein Kinase Inhibitors
205 rdf:type schema:DefinedTerm
206 Nba3926e56ef74c00bf7d64d2639a5b86 rdf:first sg:person.01272204511.68
207 rdf:rest Nafd6804f8de242c3bca4c06bda402d72
208 Nc65fce65bae4456e827240d2620b8c4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Receptor, ErbB-2
210 rdf:type schema:DefinedTerm
211 Nd406f17eadec4e23a748402c6953b7c8 rdf:first sg:person.01231307272.30
212 rdf:rest N23cae45bf97d43369ff33adc7a9f4f0e
213 Ndd9bf0c2b60b4313842475acb25c95a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Female
215 rdf:type schema:DefinedTerm
216 Ne9b6107350a64849884355895599c8d4 schema:name Springer Nature - SN SciGraph project
217 rdf:type schema:Organization
218 Nf056798079274712a03a2eed9eda875e rdf:first sg:person.01167560363.53
219 rdf:rest N5b20b007470a44c7bec7ea597b68506a
220 Nf08644a17383451fbf4edfa33affa0c2 rdf:first sg:person.01344161011.20
221 rdf:rest N96a350eea7bc407ea79c498e99559903
222 Nf276d53305c0437fa5a671575d6a6c30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Breast Neoplasms
224 rdf:type schema:DefinedTerm
225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
226 schema:name Medical and Health Sciences
227 rdf:type schema:DefinedTerm
228 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
229 schema:name Oncology and Carcinogenesis
230 rdf:type schema:DefinedTerm
231 sg:grant.2411202 http://pending.schema.org/fundedItem sg:pub.10.1038/onc.2010.626
232 rdf:type schema:MonetaryGrant
233 sg:grant.3788086 http://pending.schema.org/fundedItem sg:pub.10.1038/onc.2010.626
234 rdf:type schema:MonetaryGrant
235 sg:journal.1097543 schema:issn 0950-9232
236 1476-5594
237 schema:name Oncogene
238 schema:publisher Springer Nature
239 rdf:type schema:Periodical
240 sg:person.01052225453.31 schema:affiliation grid-institutes:grid.411083.f
241 schema:familyName Russillo
242 schema:givenName M
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052225453.31
244 rdf:type schema:Person
245 sg:person.01056647353.90 schema:affiliation grid-institutes:grid.411083.f
246 schema:familyName Markman
247 schema:givenName B
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056647353.90
249 rdf:type schema:Person
250 sg:person.01063677263.55 schema:affiliation grid-institutes:grid.32224.35
251 schema:familyName Baselga
252 schema:givenName J
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063677263.55
254 rdf:type schema:Person
255 sg:person.011163517524.50 schema:affiliation grid-institutes:grid.411083.f
256 schema:familyName Eichhorn
257 schema:givenName P J A
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011163517524.50
259 rdf:type schema:Person
260 sg:person.01124501356.03 schema:affiliation grid-institutes:grid.411083.f
261 schema:familyName Serra
262 schema:givenName V
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124501356.03
264 rdf:type schema:Person
265 sg:person.01163655237.24 schema:affiliation grid-institutes:grid.411083.f
266 schema:familyName Rodriguez
267 schema:givenName S
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163655237.24
269 rdf:type schema:Person
270 sg:person.01167560363.53 schema:affiliation grid-institutes:grid.411083.f
271 schema:familyName Gili
272 schema:givenName M
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167560363.53
274 rdf:type schema:Person
275 sg:person.01231307272.30 schema:affiliation grid-institutes:None
276 schema:familyName Arribas
277 schema:givenName J
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231307272.30
279 rdf:type schema:Person
280 sg:person.012366035415.05 schema:affiliation grid-institutes:None
281 schema:familyName Singh
282 schema:givenName S
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012366035415.05
284 rdf:type schema:Person
285 sg:person.01272204511.68 schema:affiliation grid-institutes:grid.411083.f
286 schema:familyName Prudkin
287 schema:givenName L
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272204511.68
289 rdf:type schema:Person
290 sg:person.01333626177.27 schema:affiliation grid-institutes:grid.51462.34
291 schema:familyName Rosen
292 schema:givenName N
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333626177.27
294 rdf:type schema:Person
295 sg:person.01341267404.42 schema:affiliation grid-institutes:grid.411083.f
296 schema:familyName Ibrahim
297 schema:givenName Y H
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341267404.42
299 rdf:type schema:Person
300 sg:person.01344161011.20 schema:affiliation grid-institutes:grid.411083.f
301 schema:familyName Parra
302 schema:givenName J L
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344161011.20
304 rdf:type schema:Person
305 sg:person.0717331640.11 schema:affiliation grid-institutes:grid.51462.34
306 schema:familyName Chandarlapaty
307 schema:givenName S
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717331640.11
309 rdf:type schema:Person
310 sg:person.0732111704.15 schema:affiliation grid-institutes:grid.411083.f
311 schema:familyName Rodriguez
312 schema:givenName O
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732111704.15
314 rdf:type schema:Person
315 sg:person.0746262053.25 schema:affiliation grid-institutes:grid.411083.f
316 schema:familyName Guzman
317 schema:givenName M
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746262053.25
319 rdf:type schema:Person
320 sg:person.0773414311.69 schema:affiliation grid-institutes:grid.32224.35
321 schema:familyName Scaltriti
322 schema:givenName M
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773414311.69
324 rdf:type schema:Person
325 sg:pub.10.1038/35052073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565592
326 https://doi.org/10.1038/35052073
327 rdf:type schema:CreativeWork
328 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
329 https://doi.org/10.1038/nature00766
330 rdf:type schema:CreativeWork
331 sg:pub.10.1038/nature04304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012130507
332 https://doi.org/10.1038/nature04304
333 rdf:type schema:CreativeWork
334 sg:pub.10.1038/nature05933 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023428666
335 https://doi.org/10.1038/nature05933
336 rdf:type schema:CreativeWork
337 sg:pub.10.1038/nm.1890 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000532983
338 https://doi.org/10.1038/nm.1890
339 rdf:type schema:CreativeWork
340 sg:pub.10.1038/nrc2656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035598015
341 https://doi.org/10.1038/nrc2656
342 rdf:type schema:CreativeWork
343 sg:pub.10.1038/nrc839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014023118
344 https://doi.org/10.1038/nrc839
345 rdf:type schema:CreativeWork
346 sg:pub.10.1038/nrm1962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020910010
347 https://doi.org/10.1038/nrm1962
348 rdf:type schema:CreativeWork
349 sg:pub.10.1038/onc.2008.432 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015615859
350 https://doi.org/10.1038/onc.2008.432
351 rdf:type schema:CreativeWork
352 sg:pub.10.1038/onc.2008.490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044836961
353 https://doi.org/10.1038/onc.2008.490
354 rdf:type schema:CreativeWork
355 grid-institutes:None schema:alternateName Institució Catalana de Recerca i Estudis Acançats, Barcelona, Spain
356 Prometheus Therapeutics and Diagnostics, San Diego, CA, USA
357 schema:name Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
358 Institució Catalana de Recerca i Estudis Acançats, Barcelona, Spain
359 Prometheus Therapeutics and Diagnostics, San Diego, CA, USA
360 Universitat Autònoma de Barcelona, Barcelona, Spain
361 rdf:type schema:Organization
362 grid-institutes:grid.32224.35 schema:alternateName Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA
363 Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
364 schema:name Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, USA
365 Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
366 Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
367 Experimental Therapeutics Program, Vall d′Hebron Institute of Oncology, Barcelona, Spain
368 Universitat Autònoma de Barcelona, Barcelona, Spain
369 rdf:type schema:Organization
370 grid-institutes:grid.411083.f schema:alternateName Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
371 Experimental Therapeutics Program, Vall d′Hebron Institute of Oncology, Barcelona, Spain
372 Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
373 Molecular Pathology Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain
374 schema:name Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
375 Experimental Therapeutics Program, Vall d′Hebron Institute of Oncology, Barcelona, Spain
376 Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
377 Molecular Pathology Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain
378 rdf:type schema:Organization
379 grid-institutes:grid.51462.34 schema:alternateName Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
380 schema:name Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
381 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...